A clearer roadmap for decentralized clinical trials will enable companies to better plan and more quickly advance their adoption of these strategies, which have the potential of benefiting patients and drug developers alike.
Rest-of-world markets offer good opportunities for rare disease companies to expand their sales potential beyond what U.S. & E.U. markets offer, and the requirements for market entry should be considered at a high level early on.
There is an urgent need for effective biomarkers to help classify COVID-19 patients based on risk, so that aggressive monitoring and appropriate therapy can be promptly directed to those more likely to get more severe illness.
As the COVID-19 pandemic continues to rage across the world, companies and national interests are racing to develop and secure access to SARS-CoV-2 vaccines and treatments. Over 180 vaccines are in various stages of development, with a handful having entered Phase 3 testing.